Recently Viewed

News Announcement

Parabolic Drugs: Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal

16-Jan-2021 Follow Value Research Online on Google download pdfDownload PDF Parabolic Drugs

Compliance/Disclosure requirement pursuant to Regulation 30(2) read with clause m of Sub-Part A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for Parabolic Drugs Limited which was undergone through Corporate Insolvency Resolution Process (CIRP).

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.